AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSO) for the import, sale, and distribution of Durvalumab.
Shares of AstraZeneca Pharma India surged by 13% during Tuesday’s trading session, reaching an intraday high of ₹7,598. The stock has recorded a 34% gain in 2024 so far.
Durvalumab, combined with chemotherapy, is approved as a neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) with tumors over 4 cm or node-positive, excluding EGFR mutations or ALK rearrangements.
Post-surgery, the treatment will continue with Imfinzi alone. The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals. This regulatory approval is expected to support the company’s expansion in the Indian market.
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
